Eli Lilly (LLY)
812.69
+7.26 (0.90%)
NYSE · Last Trade: Jul 25th, 11:15 PM EDT
Detailed Quote
Previous Close | 805.43 |
---|---|
Open | 809.00 |
Bid | 811.00 |
Ask | 812.00 |
Day's Range | 802.37 - 815.19 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,976,881 |
Market Cap | 777.40B |
PE Ratio (TTM) | 66.13 |
EPS (TTM) | 12.3 |
Dividend & Yield | 6.000 (0.74%) |
1 Month Average Volume | 2,968,864 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them!
Via The Motley Fool · July 25, 2025
Via The Motley Fool · July 25, 2025
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market.
Via Benzinga · July 25, 2025
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.
Via Benzinga · July 25, 2025
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
Via Benzinga · July 25, 2025
Via Benzinga · July 24, 2025
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside
Via MarketBeat · July 23, 2025
Via Benzinga · July 23, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors.
Via The Motley Fool · July 23, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Via The Motley Fool · July 22, 2025
Buy-and-hold investing only works if you choose the right companies. Here are some potential examples.
Via The Motley Fool · July 22, 2025
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.
Via Stocktwits · July 21, 2025
Via The Motley Fool · July 21, 2025
Via The Motley Fool · July 21, 2025
Via The Motley Fool · July 20, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via The Motley Fool · July 19, 2025
Via The Motley Fool · July 18, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · July 17, 2025
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.
Via Benzinga · July 17, 2025